永安药业(002365.SZ)拟与盈美加共同向美深贸易提供总额不超600万元财务资助
格隆汇 3 月 19日丨永安药业(002365.SZ)公布,公司于2021年3月19日召开第五届董事会第二十一次会议,审议通过《关于为美深(武汉)贸易有限公司提供财务资助的议案》,同意公司与关联方盈美加科技(武汉)合伙企业(有限合伙)(“盈美加”)共同向美深(武汉)贸易有限公司(“美深贸易”)提供总额不超过600万元的财务资助,用于其补充临时的资金流动性需要。此次财务资助公司与关联股东按比例提供,其中公司以自有资金提供财务资助的总额不超过477.54万元,盈美加提供财务资助的总额不超过122.46万元。借款期限自第一笔借款汇入美深贸易指定银行账户之日起至2021年12月31日,借款按年利率4.00%收取。具体借款金额以美深贸易实际需要为准,美深贸易可以提前还款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.